RadNet’s Aidence AI subsidiary and Google Health enter into agreement to bring lung cancer screening model to market

pharmafile | November 30, 2022 | News story | Research and Development  

Aidence, an AI subsidiary of RadNet which looks at lung health, has partnered with Google Health to license Google Health’s AI research model for lung nodule malignancy prediction on CT imaging. Aidence will develop, validate and bring this model into the market to support the early and accurate diagnosis of lung cancer and the reduction of unnecessary procedures in screening programmes.


Lung cancer screening with low-dose CT has been shown to significantly reduce lung cancer mortality by as much as 24% for men and 33% for women, according to the 2020 NELSON trial. However, a major difficulty in lung cancer screening is establishing the nature of detected lung nodules, because most will not be cancerous. Properly identifying and diagnosing such nodules can be time-consuming, costly and sometimes invasive, requiring follow-up CTs for those who have had surgical interventions.


To combat this, Aidence and Google Health plan to complete an AI application for lung nodule malignancy prediction: Google Health will provide its scientific expertise and Aidence will further develop the model and bring it to market.


Mark-Jan Harte, Aidence co-founder and CEO, said, “Our mission at Aidence is to give lung cancer patients a fighting chance. This strategic partnership with Google Health allows us to accelerate and expand our efforts toward achieving it. We are enthusiastic about working on a powerful deep learning model for lung nodule malignancy prediction based on the work of the Aidence and Google teams, as well as making sure that all the other requirements that contribute to the successful deployment of AI in clinical practice are in place, like clinical validation, certification and integration into the clinical workflow.”


Akib Uddin, Product Manager at Google Health, commented, “At Google Health, we want to be an active, catalytic force in demonstrating the real-world benefits of AI in health. We know just how important lung cancer screening is in saving lives, and we are excited to play a role in driving impact at scale by enabling great partners like Aidence with our research.”


James Spargo

Related Content

No items found

Latest content